{"disease":{"id":"mucopolysaccharidosis-ii","name":"mucopolysaccharidosis ii"},"drugs":{"marketed":[{"drug_id":"elaprase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elaprase","company_name":"Shire","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"hunterase","indication_name":"Mucopolysaccharidosis type II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hunterase","company_name":"Green Cross Corporation","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"idursulfase-beta","indication_name":"Mucopolysaccharidosis type II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hunterase","generic_name":"IDURSULFASE BETA","company_name":"Clinigen K.K.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"vestronidase-alfa","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepsevii","generic_name":"VESTRONIDASE ALFA","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Lysosomal beta Glucuronidase [EPC]","quality_score":10,"revenue":null,"mechanism":"Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII."},{"drug_id":"idursulfase","indication_name":"Mucopolysaccharidosis, MPS-II","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elaprase","generic_name":"IDURSULFASE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body."},{"drug_id":"vestronidase-alfa-vjbk","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MEPSEVII","generic_name":"VESTRONIDASE ALFA-VJBK","company_name":"ULTRAGENYX PHARM INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mepsevii","indication_name":"Mucopolysaccharidosis, MPS-VII","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mepsevii","company_name":"Ultragenyx Pharmaceutical Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05619900","title":"Registry of Patients Diagnosed With Lysosomal Storage Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT00069641","title":"Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00630747","title":"Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04573023","title":"A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05594992","title":"An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":80,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06022380","title":"Core Outcome Set for Head, Neck and Respiratory Disease in Mucopolysaccharidosis II","phase":"","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Manchester University NHS Foundation Trust","has_results":false},{"nct_id":"NCT03529786","title":"Mucopolysaccharidosis Type II Natural History","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT03161171","title":"Parental Coping With Challenging Behavior in Mucopolysaccharidosis Type I-III","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT03568175","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis II","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT00607386","title":"Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04348136","title":"An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04018755","title":"Open-label Study of Anakinra in MPS III","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Lynda E Polgreen","has_results":false},{"nct_id":"NCT04539340","title":"A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT03708965","title":"An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03359213","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06475404","title":"A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT04007536","title":"A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Denali Therapeutics Inc.","has_results":false},{"nct_id":"NCT05523206","title":"A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Sanguine Biosciences","has_results":false},{"nct_id":"NCT06095388","title":"Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03128593","title":"A Study of JR-141 in Patients With Mucopolysaccharidosis Type II","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04628871","title":"Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Sangamo Therapeutics","has_results":false},{"nct_id":"NCT02432144","title":"A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT02324049","title":"Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01330277","title":"Biomarkers for Hunter Syndrome","phase":"","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT01602601","title":"A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06488924","title":"An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"JCR Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03041324","title":"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sangamo Therapeutics","has_results":true},{"nct_id":"NCT02418455","title":"Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT04571970","title":"RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT04976231","title":"MPS II Immunophenotyping","phase":"","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04088734","title":"Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":true},{"nct_id":"NCT04201405","title":"Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT02618512","title":"A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04655911","title":"A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101","phase":"","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":false},{"nct_id":"NCT03775174","title":"Expanded Access to Mepsevii","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Ultragenyx Pharmaceutical Inc","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}